Is Whitehawk Therapeutics, Inc. (WHWK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 26.7% / 30% | 3.3% / 30% | 15.11% / 5% | ✗ NOT HALAL |
| DJIM | 0.5% / 33% | 26.7% / 33% | 3.3% / 33% | 15.11% / 5% | ✗ NOT HALAL |
| MSCI | 1.2% / 33% | 67.2% / 33% | 8.4% / 33% | 15.11% / 5% | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 26.7% / 33% | 3.3% / 33% | 15.11% / 5% | ✗ NOT HALAL |
| FTSE | 1.2% / 33% | 67.2% / 33% | 8.4% / 50% | 15.11% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1601.1% | |
| Net Margin | -288.3% | |
| Return on Equity (ROE) | -21.8% | |
| Return on Assets (ROA) | -64.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$97M |
| Free Cash Flow | -$98M |
| Total Debt | $0 |
| Current Ratio | 10.3 |
| Total Assets | $151M |
Price & Trading
| Last Close | $3.57 |
| 50-Day MA | $3.21 |
| 200-Day MA | $2.37 |
| Avg Volume | 145K |
| Beta | 0.6 |
|
52-Week Range
$1.39
| |
About Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Whitehawk Therapeutics, Inc. (WHWK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Whitehawk Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Whitehawk Therapeutics, Inc.'s debt ratio?
Whitehawk Therapeutics, Inc.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.2%.
What are Whitehawk Therapeutics, Inc.'s key financial metrics?
Whitehawk Therapeutics, Inc. has a market capitalization of $149M, and revenue of $7M. Return on equity stands at -21.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.